GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Beneish M-Score

Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Beneish M-Score : -6.16 (As of May. 04, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -6.16 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Maravai LifeSciences Holdings's Beneish M-Score or its related term are showing as below:

MRVI' s Beneish M-Score Range Over the Past 10 Years
Min: -6.16   Med: -2.88   Max: -1.44
Current: -6.16

During the past 6 years, the highest Beneish M-Score of Maravai LifeSciences Holdings was -1.44. The lowest was -6.16. And the median was -2.88.


Maravai LifeSciences Holdings Beneish M-Score Historical Data

The historical data trend for Maravai LifeSciences Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Beneish M-Score Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -1.44 -2.88 -6.16

Maravai LifeSciences Holdings Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.88 -3.69 -3.67 -3.57 -6.16

Competitive Comparison of Maravai LifeSciences Holdings's Beneish M-Score

For the Biotechnology subindustry, Maravai LifeSciences Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maravai LifeSciences Holdings's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's Beneish M-Score falls into.



Maravai LifeSciences Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Maravai LifeSciences Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1599+0.528 * 1.6666+0.404 * 0.6577+0.892 * 0.3272+0.115 * 1.3705
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 3.5792+4.679 * -0.611531-0.327 * 1.5386
=-6.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $55.7 Mil.
Revenue was 74.141 + 66.865 + 68.914 + 79.025 = $288.9 Mil.
Gross Profit was 39.033 + 30.179 + 25.641 + 45.349 = $140.2 Mil.
Total Current Assets was $699.9 Mil.
Total Assets was $1,487.5 Mil.
Property, Plant and Equipment(Net PPE) was $222.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $48.8 Mil.
Selling, General, & Admin. Expense(SGA) was $151.4 Mil.
Total Current Liabilities was $87.5 Mil.
Long-Term Debt & Capital Lease Obligation was $598.1 Mil.
Net Income was -105.959 + -6.462 + -6.541 + -0.067 = $-119.0 Mil.
Non Operating Income was 668.166 + -3.326 + 0.797 + -1.268 = $664.4 Mil.
Cash Flow from Operations was 7.79 + 14.166 + 19.194 + 85.074 = $126.2 Mil.
Total Receivables was $146.8 Mil.
Revenue was 204.713 + 191.263 + 242.732 + 244.293 = $883.0 Mil.
Gross Profit was 151.46 + 153.087 + 205.236 + 204.261 = $714.0 Mil.
Total Current Assets was $847.9 Mil.
Total Assets was $2,282.3 Mil.
Property, Plant and Equipment(Net PPE) was $116.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $38.1 Mil.
Selling, General, & Admin. Expense(SGA) was $129.3 Mil.
Total Current Liabilities was $110.1 Mil.
Long-Term Debt & Capital Lease Obligation was $573.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(55.723 / 288.945) / (146.814 / 883.001)
=0.19285 / 0.166267
=1.1599

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(714.044 / 883.001) / (140.202 / 288.945)
=0.808656 / 0.48522
=1.6666

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (699.912 + 222.646) / 1487.45) / (1 - (847.902 + 116.59) / 2282.315)
=0.379772 / 0.577406
=0.6577

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=288.945 / 883.001
=0.3272

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(38.103 / (38.103 + 116.59)) / (48.781 / (48.781 + 222.646))
=0.246314 / 0.179721
=1.3705

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(151.39 / 288.945) / (129.259 / 883.001)
=0.523941 / 0.146386
=3.5792

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((598.114 + 87.468) / 1487.45) / ((573.553 + 110.144) / 2282.315)
=0.460911 / 0.299563
=1.5386

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-119.029 - 664.369 - 126.224) / 1487.45
=-0.611531

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Maravai LifeSciences Holdings has a M-score of -6.16 suggests that the company is unlikely to be a manipulator.


Maravai LifeSciences Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Executives
John A Deford director C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Rebecca Buzzeo officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii officer: See remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy officer: See Remarks 1620 FARADAY AVE, CARLSBAD CA 92008
Carl Hull director, officer: Chief Executive Officer 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack officer: General Counsel 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian Neel officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Christine Dolan officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121